Cavallo A, Camera E, Bottillo G, Maiellaro M, Truglio M, Marini F, Chavagnac-Bonneville M, Fauger A, Perrier E, Pigliacelli F, Picardo M, Cristaudo A, Mariano M. Biosignatures of defective sebaceous gland activity in sebum-rich and sebum-poor skin areas in adult atopic dermatitis. Exp Dermatol. 2024 Mar;33(3):e15066.
1.Clinical study under dermatological control, on 30 adult subjects with atopic dermatitis and significant pruritus using Atoderm AD Intensive baume for 7 days. Self-assessment under medical control after the first application (Argentina, 2025)2.Ex vivo study of physical protection against cat allergens penetration by Atoderm AD Intensive baume on skin biopsies, versus untreated condition. Quantification by immunostaining and image analysis. Other allergens were also tested: -85% peanut allergens, -81% mold allergens, -71% house dust mite allergens (France, 2025).3.Clinical study on 10 subjects, evaluation of physical protection of Atoderm AD Intensive baume against pollution particles deposition on skin. Instrumental measure by colorimetry (France, 2024)4.In vitro study of protection efficacy of Atoderm AD Intensive baume against proliferation of Staphylococcus aureus under biofilm form, versus control condition. Counting of bacteria after 4h-incubation (France, 2024)5.Clinical study on 10 subjects for 24h, instrumental measurement of hydration by corneometry (France, 2023)6.Clinical study under dermatological control, on 32 adult subjects with irritant or allergic contact dermatitis, using Atoderm AD Intensive baume for 28 days. Self-grading (Mauritius, 2025).7.Helps space out flare-ups of severe dryness. Clinical study under dermatological control, on 88 children with light to moderate atopic dermatitis, using either Atoderm AD Intensive baume or a neutral cream, for 6 months. Self-reporting: 88% of subjects without any reported flare-ups for 6 months with Atoderm AD Intensive baume (Poland, 2024-2025).8.Ex vivo study of loricrin and filaggrin synthesis by cytokines-stressed skin biopsies, after LIPIDACTIVE technology topical application versus stressed untreated condition. Quantification by immunostaining of proteins and image analysis (France, 2024).9.Ex vivo study of ceramides synthesis by stripped skin biopsies, after LIPIDACTIVE technology topical application versus stripped untreated condition. Quantification by liquid chromatography and mass spectrometry. +51% NP long-chain ceramides (France, 2025).10.In vitro study of claudin-1 (tight junction) synthesis by stressed human primary keratinocytes, with SKIN BARRIER SEALER technology versus stressed control condition. Quantification by immunostaining of proteins and image analysis (France, 2020)11.Clinical study under dermatological control, on 43 adult subjects with moderate atopic dermatitis using either Atoderm AD Intensive baume or a neutral cream, in routine with Atoderm Huile de douche, for 37 days. Instrumental measure on non-lesional area (Georgia, winter 2025).12.Clinical study under dermatological control, on 88 children with light to moderate atopic dermatitis, using either Atoderm AD Intensive baume or a neutral cream, for 6 months. Self-grading of CDLQI, question n°3 and n°5 versus neutral cream.13.Clinical study under dermatological control, on 88 children with light to moderate atopic dermatitis, using either Atoderm AD Intensive baume or a neutral cream, for 6 months.. Clinical grading, sub-score of SCORAD (Poland, 2024-2025).